Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Payables (2016 - 2025)

Historic Payables for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $14.3 million.

  • Aytu Biopharma's Payables fell 924.19% to $14.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.3 million, marking a year-over-year decrease of 924.19%. This contributed to the annual value of $10.6 million for FY2025, which is 1658.67% down from last year.
  • Latest data reveals that Aytu Biopharma reported Payables of $14.3 million as of Q4 2025, which was down 924.19% from $12.3 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Payables high stood at $25.1 million for Q1 2023, and its period low was $9.4 million during Q3 2021.
  • Its 5-year average for Payables is $14.7 million, with a median of $14.7 million in 2022.
  • Its Payables has fluctuated over the past 5 years, first soared by 12530.1% in 2023, then crashed by 5192.22% in 2024.
  • Aytu Biopharma's Payables (Quarter) stood at $15.6 million in 2021, then increased by 15.41% to $18.0 million in 2022, then tumbled by 36.15% to $11.5 million in 2023, then surged by 36.63% to $15.7 million in 2024, then dropped by 9.24% to $14.3 million in 2025.
  • Its last three reported values are $14.3 million in Q4 2025, $12.3 million for Q3 2025, and $10.6 million during Q2 2025.